Pruvanserin

Drug Profile

Pruvanserin

Alternative Names: EMD 281014; LSN2411347; LY-2422347

Latest Information Update: 19 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer Eli Lilly; Newron Pharmaceuticals
  • Class Piperazines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported CNS disorders
  • Discontinued Insomnia; Major depressive disorder

Most Recent Events

  • 19 Aug 2014 No development reported - Phase-I for CNS disorders in Italy (PO)
  • 21 Aug 2012 Phase-I clinical trials in CNS disorders in Italy (unspecified route)
  • 05 Apr 2011 Discontinued - Phase-II for Insomnia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top